Peter U. Park PhD

Peter Park is a Chief Scientific Officer at the Orum Therapeutics. Before that, he was Vice President of Biology at Mersana Therapeutics, Inc., where he co-invented and lead the discovery of novel antibody-drug conjugates (ADC), including upifitamab rilsodotin. Prior to that, Peter served at ImmunoGen, Inc. for 10 years, most recently as Senior Director of Discovery Research. In this role, he managed the discovery research portfolio for the development of novel monoclonal antibodies and antibody-drug conjugates for oncology, He co-invented and advanced many clinical candidates, including Sarclisa (Isatuximab; SAR650984) which was licensed to Sanofi. He oversaw three departments that included Discovery Research, Antibody Engineering, and Cell Line Development. Peter received his Ph.D. and B.S. in Biology from MIT.